Universal Registration Document Including The Annual Financial Report

Overview

The report describes the company’s 2019 clinical-stage portfolio, including positive Step 1 results for Tedopi® in advanced non-small cell lung cancer and positive Phase 1 results for OSE-127. Consolidated revenue was €25,952,000, mainly generated through licensing and collaboration agreements. The company reported 42 employees at December 31, 2019 and stated that its activities released neither significant environmental emissions nor greenhouse gases.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2019
Period: 1 January 2019 – 31 December 2019
Publication date: 15 April 2020
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services